Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...

Novo Nordisk received approval from the Food and Drug Administration for three new indications of Sogroya, a growth hormone.

Many growth stocks have been hammered in 2026. The market -- and seemingly the whole world -- is worried about how artificial intelligence (AI) will disrupt the economy. Smart investors know that when ...

With a pullback in some tech stocks over the last week, it's a good time to go hunting for ideas. One stock worth taking a closer look at after declining over the last week is social media company ...

One company dominates the AI chip market, and that will help it record terrific growth over the next five years. The other growth stock is up more than 180% in the past six months, and favorable ...

Even in environments where tech and growth stocks are outperforming, dividend ETFs still deserve a spot in diversified portfolios. The sharp market rotation and emergence of dividend stocks in 2026 ...

Learn how Michu, an Australian-founded pet brand, became a Smart50 winner, sold 6 million bags of tofu litter and grew into a global cat care leader.

January trading data confirm a solid start to the year, while updated medium-term targets point to accelerating operating leverage, with EBITDA growth expected to outpace revenue growth through 2028.

On February 19, Tom Lee of Fundstrat and BitMine joined ‘Closing Bell’ on CNBC to talk about the state of the markets. Lee described the current market environment as a slow turnaround following a ...

My last coverage on the Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) was published on Nov 10, 2025. The analysis rated VIG as a buy after examining its past earnings growth rates (which were ...